tiprankstipranks
Trending News
More News >
Restart Life Sciences (NMLSF)
OTHER OTC:NMLSF
Advertisement

Restart Life Sciences (NMLSF) Stock Statistics & Valuation Metrics

Compare
30 Followers

Total Valuation

Restart Life Sciences has a market cap or net worth of $1.81M. The enterprise value is $1.92M.
Market Cap$1.81M
Enterprise Value$1.92M

Share Statistics

Restart Life Sciences has 36,050,354 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,050,354
Owned by Insiders
Owned by Institutions

Financial Efficiency

Restart Life Sciences’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is 300.42%.
Return on Equity (ROE)-0.75
Return on Assets (ROA)1.18
Return on Invested Capital (ROIC)300.42%
Return on Capital Employed (ROCE)2.20
Revenue Per Employee
Profits Per Employee10.00T>
Employee Count
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Restart Life Sciences is 4.8. Restart Life Sciences’s PEG ratio is -0.02.
PE Ratio4.8
PS Ratio0.00
PB Ratio-3.07
Price to Fair Value-3.07
Price to FCF-12.78
Price to Operating Cash Flow-4.10
PEG Ratio-0.02

Income Statement

In the last 12 months, Restart Life Sciences had revenue of 0.00 and earned 224.75K in profits. Earnings per share was 0.01.
Revenue0.00
Gross Profit0.00
Operating Income-658.51K
Pretax Income224.75K
Net Income224.75K
EBITDA-656.20K
Earnings Per Share (EPS)0.01

Cash Flow

In the last 12 months, operating cash flow was -260.75K and capital expenditures 0.00, giving a free cash flow of -260.75K billion.
Operating Cash Flow-260.75K
Free Cash Flow-260.75K
Free Cash Flow per Share>-0.01

Dividends & Yields

Restart Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta3.27
52-Week Price Change-44.44%
50-Day Moving Average0.07
200-Day Moving Average0.06
Relative Strength Index (RSI)22.63
Average Volume (3m)116.00

Important Dates

Restart Life Sciences upcoming earnings date is Nov 26, 2025, TBA (Confirmed).
Last Earnings DateAug 22, 2025
Next Earnings DateNov 26, 2025
Ex-Dividend Date

Financial Position

Restart Life Sciences as a current ratio of 0.37, with Debt / Equity ratio of 0.00%
Current Ratio0.37
Quick Ratio0.37
Debt to Market Cap0.09
Net Debt to EBITDA-0.10
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Restart Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Restart Life Sciences EV to EBITDA ratio is -1.50, with an EV/FCF ratio of -13.73.
EV to Sales0.00
EV to EBITDA-1.50
EV to Free Cash Flow-13.73
EV to Operating Cash Flow-13.73

Balance Sheet

Restart Life Sciences has $388.31K in cash and marketable securities with $0.00 in debt, giving a net cash position of $388.31K billion.
Cash & Marketable Securities$388.31K
Total Debt$0.00
Net Cash$388.31K
Net Cash Per Share$0.01
Tangible Book Value Per Share-$0.02

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Restart Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis